To advance scientific knowledge and develop treatments and cures for breast cancer, the Extramural Grants Administration Program staff will issue requests for applications on behalf of the Health Research Science Board. Check this web site for updates, or sign up for HRSB eAlerts and indicate Request for Applications (RFA) as your area of interest.
Click here for tips on managing graphics and file sizes submitted with your RFA or RFP.
Anticipated Funding Opportunity
- Healthcare Practitioner Breast Cancer Education Research Projects (Round 2)
Current Funding Opportunities
-
Patricia S. Brown Breast Cancer Risk Reduction Education Research Projects (Round 6): The purpose of this RFA is to encourage the development and implementation of innovative pilot projects in breast cancer risk reduction education with rigorous evaluation and revision. Successful applications will propose the design of new educational strategies to elicit behavior changes intended to reduce specific risk factors associated with developing breast cancer. The applicant must be a New York State not-for-profit community-based organization (CBO) or an accredited academic institution within New York with authority to confer graduate degrees in medicine, physician assistant, nursing, health education or public health studies. All applicants must enter into a partnership. The partnership must be between an academic institution and a CBO (see RFA for eligibility specifics). Approximately $270,000 is available to support approximately one (1) award from this RFA. The funding is available for a period of up to three years. To learn more about this opportunity, please visit the New York State Grants Gateway (link is external) and search using the keywords, Patricia S. Brown, and select the Department of Health as the Funding Agency. Letters of Intent are strongly encouraged and due by October 16, 2018. Applications are due by 4:00 PM EST on January 3, 2019 in the New York State Grants Gateway.
-
Peter T. Rowley Breast Cancer Scientific Research Projects (Round 5): This RFA provides funding for researchers to try new methods and approaches in breast cancer research. These projects are self-contained research projects. They are not intended to fund smaller components of larger research projects, solely for data collection, for incremental or correlative research aims, or for compression of a larger project into a smaller time frame. Responsive applications include the following projects: highly speculative, exploratory, or high-risk; may not have preliminary data, but have the potential for high scientific payoff; application or development of state-of-the-art technologies, tools or resources for breast cancer research; innovative or developmental; focus on exceptionally promising topics and have some pilot data, but not yet sufficiently mature to compete successfully for funding for a full-scale study and/or; testing new hypotheses based on research grounded in a non-breast cancer research area. Approximately $2.16 million will be available through this RFA to support approximately five to seven awards. The funding is for a period of two years. To download a copy of the RFA and instructions, visit the New York State Grants Gateway (link is external) and search using the keywords, Peter T. Rowley, and select the Department of Health as the Funding Agency. Letters of Intent are strongly encouraged and due by October 18, 2018. Applications are due by 4:00 PM EST on December 6, 2018 in the New York State Grants Gateway.
Recent Awards
- Peter T. Rowley Breast Cancer Scientific Research Projects RFA (Round 4). These projects are two-year awards.
| Principal Investigator | Sponsoring Institution | Amount | Title |
|---|---|---|---|
|
Scott A. Coonrod, Ph.D. |
Cornell University | $358,832 | Histone Citrullination in Estrogen Receptor Signaling and Breast Cancer |
| Jo L. Feudenheim, Ph.D. | University at Buffalo | $359,024 | The Microbiome in the Etiology and Prevention of Breast Cancer |
|
Jun Lin, M.D., Ph.D. |
Stony Brook University | $360,000 | Effects of Anesthetics on Lung Metastasis in Mouse Models of Breast Cancer |
| Cristina Montagna, Ph.D. | Albert Einstein College of Medicine | $360,000 | Somatic Mutation Rate in Mammary Epithelial Cells and Peripheral B-Lymphocytes as Risk Factor for Breast Cancer |
|
Harry Ostrer, M.D. |
Albert Einstein College of Medicine | $326,910 | High Throughput Functional Genomics to Guide Precision Care |
| Jonathan C. Pertruccelli, Ph.D., | University at Albany | $335,905 | A Simultaneous Phase and Scatter Imaging Towards a Clinical System for Early Stage Breast Cancer Diagnosis |
| Jose Silva, Ph.D. | Icahn School of Medicine at Mount Sinai | $360,000 | Sensing Cell Geometry: A Novel Checkpoint Critical for Breast Tumor Suppression |
- Patricia S. Brown Breast Cancer Risk Reduction Education Research Projects RFA (Round 5). These projects are three-year awards.
| Principal Investigator | Sponsoring Institution | Amount | Title |
|---|---|---|---|
| Lina Jandorf, M.A. | Icahn School of Medicine at Mount Sinai | $268,599 | Development of an Intergenerational Breast Health Community Education Program for Black Women: Reducing the Risk for Triple Negative Breast Cancer in Black Women through Breastfeeding |
| Jin Young Seo, Ph.D. | The Research Foundation of CUNY, Hunter College | $245,002 | A Culturally Tailored Education Program to Reduce Breast Cancer Risk in Korean Immigrant Women |
- Peter T. Rowley Breast Cancer Scientific Research Projects RFA (Round 3). These projects are two-year awards.
| Principal Investigator | Sponsoring Institution | Amount | Title |
|---|---|---|---|
| Chia-Hsin Chan, Ph.D. | The Research Foundation for SUNY Stony Brook | $359,999 | A New Strategy and Tool to Tackle Cancer Stem Cells and Metastasis in Triple-negative Breast Cancer |
|
Mikala Egeblad, Ph.D. |
Cold Spring Harbor Laboratory | $345,800 | Modulating Innate-adaptive Immune Cell Interactions for the Immunotherapy of Breast Cancer |
| Sharon S. Evans, Ph.D. | Health Research Incorporated, Roswell Park Cancer Institute | $360,000 | Novel Mechanism of Immune Subversion by Myeloid-Derived Suppressor Cells in Aggressive Breast Cancer |
| John G. Frelinger, Ph.D. | University of Rochester | $357,747 | Amplifying Immune Responses to Breast Cancer Using a Novel IL.2 Therapy to Limit Side Effects and Enhance Efficacy |
| David Jeruzalmi, Ph.D. | The Research Foundation of CUNY obo City College of New York | $347,200 | Laying the Foundation for Combination Therapy Against Breast Cancer: Analysis of Human Shelterin-DNA Complex |
| Mira Krendel, Ph.D. | The Research Foundation for SUNY Upstate Medical University | $360,000 | Myosin 1e as a Potential Therapeutic Target in Breast Cancer |
| Juntao Luo, Ph.D. | State University of New York Upstate Medical University | $360,000 | Structure-based Nanocarrier Design for Targeted Cabazitaxel Delivery to the Advanced Breast Cancer Brain Metastases |
| Mark Noble, Ph.D. | University of Rochester | $359,907 | Safer and More Effective Treatment of Luminal Breast Cancer and Overcoming Tamoxifen Resistance |
|
Scott Powers, Ph.D. |
The Research Foundation for SUNY Stony Brook | $350,302 | Single-cell Barcoding to Study Breast Cancer Evolution and Drug Resistance |
|
Robert J. Schneider, Ph.D. |
New York University School of Medicine | $360,000 | Reversing Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer |
- Peter T. Rowley Breast Cancer Research Project and Postdoctoral Fellowship Awards RFA (Round 2): A total of $3,597,800 million in Peter T. Rowley Breast Cancer Research Project and Postdoctoral Fellowship Awards RFA awards were made in 2011, providing initial support for preliminary testing of novel or exploratory hypotheses related to breast cancer. Recipients are expected to open a new area of investigation, satisfactorily test a novel hypothesis, or produce viable data for preparation of a full-scale research application to another organization. Awards were made to eight investigators, with a maximum of $360,000 for two-year projects.
| Principal Investigator | Sponsoring Institution | Amount | Title |
|---|---|---|---|
| Anne R. Bresnick, Ph.D. | Albert Einstein College of Medicine | $360,000 | Stromal Contribution of the S100A4 Metastasis Factor to Tumor Invasion |
| Pamela Cowin, Ph.D. | New York University School of Medicine | $360,000 | The Role of Gpr 125 in Breast Development and Cancer |
| Johanna A. Joyce, Ph.D. | Sloan-Kettering Institute for Cancer Research | $360,000 | Investigating and Targeting Interactions Between Cancer and the Microenvironment in Breast to Brain Metastasis |
| Paraic A. Kenny, Ph.D. | Albert Einstein College of Medicine | $360,000 | Consequences of GATA3 Mutation for Normal Mammary Gland Development and Breast Cancer |
| Xiaojing Ma, Ph.D. | Weill Cornell Medical College | $360,000 | Targeting CCL5 in Triple Negative Breast Cancer |
| Jeffrey W. Pollard, Ph.D. | Albert Einstein College of Medicine | $360,000 | Macrophages and Immunosuppression in Breast Cancer |
| Elizabeth A. Repasky, Ph.D. | Roswell Park Cancer Institute | $357,000 | Is the Immune Response Against Breast Cancer Inhibited by Lack of Available Metabolic Energy? |
| Rodney Rothstein, Ph.D. | Columbia University | $360,000 | Developing a New Paradigm to Discover Novel Breast Cancer Drug Targets |
Print